RedHill Biopharma Ltd – (NASDAQ:RDHL)‘s stock had its “outperform” rating restated by research analysts at FBR & Co in a report released on Friday. They currently have a $25.00 price target on the stock, down from their previous price target of $36.00. FBR & Co’s price objective indicates a potential upside of 165.11% from the […]
